Patent intelligence · CA
CA 2591889
TRAITEMENT DE LA DEPRESSION MELANCOLIQUE SEVERE A L'AIDE D'EPA
TRAITEMENT DE LA DEPRESSION MELANCOLIQUE SEVERE A L'AIDE D'EPA
Patent details — CA 2591889
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Jun 29, 2006
- Expiration
- Jun 24, 2026
- Applicant
- AMARIN NEUROSCIENCE LTD [GB]
- CPC classes
- A61K 31/ 20 A I, A61K/3120, A61K/31202, A61P 25/ 24 A I
Quick answer
CA 2591889 (TRAITEMENT DE LA DEPRESSION MELANCOLIQUE SEVERE A L'AIDE D'EPA) is held by AMARIN NEUROSCIENCE LTD [GB]. Status: granted. Granted Jun 29, 2006. Expires Jun 24, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMARIN NEUROSCIENCE LTD [GB]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 20 A I, A61K/3120, A61K/31202, A61P 25/ 24 A I, A61P/2524, A61P/4300
More from AMARIN NEUROSCIENCE LTD [GB]
Related pharmaceutical patents in our USPTO index.
-
CA 2754902
COMPOSES D'ACIDE GRAS ESSENTIEL
granted -
IL 159038
USE OF COENZYME Q AND EICOSAPENTAENOIC ACID (EPA) FOR THE PREPARATION OF MEDICAMENTS
granted -
DK 1007053
Behandling af smerte
granted -
SI 1148873
HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES FOR NEUROLOGICAL DISORDERS
expired -
IS 7744
Eikósapentanó sýra (EPA) til notkunar við meðhöndlun á lystarstoli (AN) og matgræðgi
expired -
CA 2506727
TRAITEMENT DE LA MALADIE DE HUNTINGTON AU MOYEN D'ACIDE EICOSAPENTAENOIQUE
expired -
EP 1392276
VERSTÄRKTE WIRKUNG MEHRFACH UNGESÄTTIGTER FETTSÄUREN
expired
Frequently asked questions
What is US patent 2591889?
CA 2591889 (TRAITEMENT DE LA DEPRESSION MELANCOLIQUE SEVERE A L'AIDE D'EPA) is held by AMARIN NEUROSCIENCE LTD [GB]. Status: granted. Granted Jun 29, 2006. Expires Jun 24, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2591889?
AMARIN NEUROSCIENCE LTD [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does CA 2591889 expire?
Our index shows an expiration date of Jun 24, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.